

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: tba

Filed: tba

1<sup>st</sup> Inventor: Kaneyoshi KATO

For: Melanin Concentrating Hormone Antagonist

Atty. Dkt. No. 2648 USOP

Art Unit: tba

Examiner: tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

BOX Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449. A legible copy of each listed reference is herewith being provided to the Examiner.


Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: March 19, 2001

(847) 383-3372

(847) 383-3391



Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

Application No.:	tsa	Art Unit:	tsa
Filed:	tsa	Examiner:	tsa
1 <sup>st</sup> Inventor:	K. KATO	Allowed:	
For:	Melanin Concentrating Hormone Antagonist	Batch:	
Atty Dkt. No.	2648 USOP	Paper No.:	

The USPTO is requested to kindly acknowledge receipt of the following items:

1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
3. Copy of Request form of the International Application PCT/JP0006375, (Form PCT/RO/101)(4 pages)
4. Specification - total 352 pages, including Claims 1-38 (pages 336-352), Abstract (1 page) and Sequence Listing (11 pages)
5. Copy of Forms PCT/IB/301, 304, 308 and 332 (6 pages)
6. Copy of the front page of the International Application as published (WO 01/21577) (1 page)
7. Copy of International Preliminary Examination Report (8 pages)
8. Copy of International Search Report (8 pages)
9. Copy of Written Opinion (PCT/IPEA/408) (8 pages)
10. First Preliminary Amendment (19 pages)
11. Information Disclosure Statement (1 page) with Form PTO 1449 (1 page), and cited references (15)
12. Assignment (2 pages) and Recordation Cover Sheet (1 page X 2)
13. Declaration and Power of Attorney (5 pages)

Respectfully submitted 3/19/02 For Customer No. 23,115  
Express Mail Label No. EL 916492917US  
By Mark Chao, PhD, JD - Reg. No. 37,293

10/088771  
JC07 Rec'd PCT/PTO 9 MAR 2002

Application No.:	tsa	Art Unit:	tsa
Filed:	tsa	Examiner:	tsa
1 <sup>st</sup> Inventor:	K. KATO	Allowed:	
For:	Melanin Concentrating Hormone Antagonist	Batch:	
Atty Dkt. No.	2648 USOP	Paper No.:	

The USPTO is requested to kindly acknowledge receipt of the following items:

1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
3. Copy of Request form of the International Application PCT/JP0006375, (Form PCT/RO/101)(4 pages)
4. Specification - total 352 pages, including Claims 1-38 (pages 336-352), Abstract (1 page) and Sequence Listing (11 pages)
5. Copy of Forms PCT/IB/301, 304, 308 and 332 (6 pages)
6. Copy of the front page of the International Application as published (WO 01/21577) (1 page)
7. Copy of International Preliminary Examination Report (8 pages)
8. Copy of International Search Report (8 pages)
9. Copy of Written Opinion (PCT/IPEA/408) (8 pages)
10. First Preliminary Amendment (19 pages)
11. Information Disclosure Statement (1 page) with Form PTO 1449 (1 page), and cited references (15)
12. Assignment (2 pages) and Recordation Cover Sheet (1 page X 2)
13. Declaration and Power of Attorney (5 pages)

Respectfully submitted 3/19/02 For Customer No. 23,115  
Express Mail Label No. EL 916492917US  
By Mark Chao, PhD, JD - Reg. No. 37,293

Page 1 of 1																																																																																																							
FORM PTO 1449 (modified)	ATTY DOCKET NO.: 2648 USOP																																																																																																						
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)	SERIAL NO.: tba																																																																																																						
Date Submitted to PTO:	APPLICANT: KATO, K																																																																																																						
FILING DATE: tba	GROUP: tba Examiner tba																																																																																																						
<table border="1"> <thead> <tr> <th>EXAMINER</th> <th>REF</th> <th>REFERENCE</th> <th>DATE</th> <th>CLASS</th> <th>REMARKS</th> </tr> </thead> <tbody> <tr> <td rowspan="11">MF</td> <td>A1</td> <td>WO 95/32967</td> <td>12/7/1995</td> <td>WIPO</td> <td></td> </tr> <tr> <td>A2</td> <td>WO 98/38156</td> <td>9/3/1998</td> <td>WIPO</td> <td></td> </tr> <tr> <td>A3</td> <td>WO 99/01127</td> <td>1/14/1999</td> <td>WIPO</td> <td></td> </tr> <tr> <td>A4</td> <td>DE 2108185</td> <td>9/7/1972</td> <td>EP</td> <td>Yes - Abstract only</td> </tr> <tr> <td>A5</td> <td>DE 2448257</td> <td>4/22/1976</td> <td>EP</td> <td>Yes - Abstract only</td> </tr> <tr> <td>A6</td> <td>DE 2502588</td> <td>7/29/1976</td> <td>EP</td> <td>Yes - Abstract only</td> </tr> <tr> <td>A7</td> <td>EP 0533266</td> <td>3/24/1993</td> <td>EP</td> <td></td> </tr> <tr> <td>A8</td> <td>WO 96/35671</td> <td>11/14/1996</td> <td>WIPO</td> <td></td> </tr> <tr> <td>A9</td> <td>EP 0920864</td> <td>6/9/1999</td> <td>EP</td> <td></td> </tr> <tr> <td>A10</td> <td>WO 98/15274</td> <td>4/16/1998</td> <td>WIPO</td> <td></td> </tr> <tr> <td>A11</td> <td>WP 99/52857</td> <td>10/21/1999</td> <td>WIPO</td> <td></td> </tr> <tr> <td colspan="6"> <table border="1"> <thead> <tr> <th>EXAMINER</th> <th>REF</th> <th>REFERENCE</th> <th>DATE</th> <th>CLASS</th> <th>REMARKS</th> </tr> </thead> <tbody> <tr> <td rowspan="5">MF</td> <td>A12</td> <td>Mewshaw, et al. "New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D<sub>2</sub> Agonist Pharmacophore. Structure-Activity Relationships of a Series of 2-(Aminomethyl)chromans" JOURNAL OF MEDICINAL CHEMISTRY 40:4235-56 (1997)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>A13</td> <td>Birch, et al. "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D<sub>2</sub> Antagonists/5-HT<sub>1A</sub> Partial Agonists with Potential as Atypical Antipsychotic Agents" JOURNAL OF MEDICINAL CHEMISTRY 42:3342-55(1999)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>A14</td> <td>Qu, et al. "A role for melanin-concentrating hormone in the central regulation of feeding behaviour: Nature 380:243-247(21 March 1996)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>A15</td> <td>Beilstein Registry Number 5345411, XP-002155831, (5/4/1993)</td> <td></td> <td></td> <td></td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> </td> </tr> <tr> <td>EXAMINER: <i>MF</i></td> <td>DATE CONSIDERED: 4/27/2005</td> </tr> </tbody></table>		EXAMINER	REF	REFERENCE	DATE	CLASS	REMARKS	MF	A1	WO 95/32967	12/7/1995	WIPO		A2	WO 98/38156	9/3/1998	WIPO		A3	WO 99/01127	1/14/1999	WIPO		A4	DE 2108185	9/7/1972	EP	Yes - Abstract only	A5	DE 2448257	4/22/1976	EP	Yes - Abstract only	A6	DE 2502588	7/29/1976	EP	Yes - Abstract only	A7	EP 0533266	3/24/1993	EP		A8	WO 96/35671	11/14/1996	WIPO		A9	EP 0920864	6/9/1999	EP		A10	WO 98/15274	4/16/1998	WIPO		A11	WP 99/52857	10/21/1999	WIPO		<table border="1"> <thead> <tr> <th>EXAMINER</th> <th>REF</th> <th>REFERENCE</th> <th>DATE</th> <th>CLASS</th> <th>REMARKS</th> </tr> </thead> <tbody> <tr> <td rowspan="5">MF</td> <td>A12</td> <td>Mewshaw, et al. "New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D<sub>2</sub> Agonist Pharmacophore. Structure-Activity Relationships of a Series of 2-(Aminomethyl)chromans" JOURNAL OF MEDICINAL CHEMISTRY 40:4235-56 (1997)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>A13</td> <td>Birch, et al. "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D<sub>2</sub> Antagonists/5-HT<sub>1A</sub> Partial Agonists with Potential as Atypical Antipsychotic Agents" JOURNAL OF MEDICINAL CHEMISTRY 42:3342-55(1999)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>A14</td> <td>Qu, et al. "A role for melanin-concentrating hormone in the central regulation of feeding behaviour: Nature 380:243-247(21 March 1996)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>A15</td> <td>Beilstein Registry Number 5345411, XP-002155831, (5/4/1993)</td> <td></td> <td></td> <td></td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>						EXAMINER	REF	REFERENCE	DATE	CLASS	REMARKS	MF	A12	Mewshaw, et al. "New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D <sub>2</sub> Agonist Pharmacophore. Structure-Activity Relationships of a Series of 2-(Aminomethyl)chromans" JOURNAL OF MEDICINAL CHEMISTRY 40:4235-56 (1997)				A13	Birch, et al. "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D <sub>2</sub> Antagonists/5-HT <sub>1A</sub> Partial Agonists with Potential as Atypical Antipsychotic Agents" JOURNAL OF MEDICINAL CHEMISTRY 42:3342-55(1999)				A14	Qu, et al. "A role for melanin-concentrating hormone in the central regulation of feeding behaviour: Nature 380:243-247(21 March 1996)				A15	Beilstein Registry Number 5345411, XP-002155831, (5/4/1993)									EXAMINER: <i>MF</i>	DATE CONSIDERED: 4/27/2005
EXAMINER	REF	REFERENCE	DATE	CLASS	REMARKS																																																																																																		
MF	A1	WO 95/32967	12/7/1995	WIPO																																																																																																			
	A2	WO 98/38156	9/3/1998	WIPO																																																																																																			
	A3	WO 99/01127	1/14/1999	WIPO																																																																																																			
	A4	DE 2108185	9/7/1972	EP	Yes - Abstract only																																																																																																		
	A5	DE 2448257	4/22/1976	EP	Yes - Abstract only																																																																																																		
	A6	DE 2502588	7/29/1976	EP	Yes - Abstract only																																																																																																		
	A7	EP 0533266	3/24/1993	EP																																																																																																			
	A8	WO 96/35671	11/14/1996	WIPO																																																																																																			
	A9	EP 0920864	6/9/1999	EP																																																																																																			
	A10	WO 98/15274	4/16/1998	WIPO																																																																																																			
	A11	WP 99/52857	10/21/1999	WIPO																																																																																																			
<table border="1"> <thead> <tr> <th>EXAMINER</th> <th>REF</th> <th>REFERENCE</th> <th>DATE</th> <th>CLASS</th> <th>REMARKS</th> </tr> </thead> <tbody> <tr> <td rowspan="5">MF</td> <td>A12</td> <td>Mewshaw, et al. "New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D<sub>2</sub> Agonist Pharmacophore. Structure-Activity Relationships of a Series of 2-(Aminomethyl)chromans" JOURNAL OF MEDICINAL CHEMISTRY 40:4235-56 (1997)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>A13</td> <td>Birch, et al. "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D<sub>2</sub> Antagonists/5-HT<sub>1A</sub> Partial Agonists with Potential as Atypical Antipsychotic Agents" JOURNAL OF MEDICINAL CHEMISTRY 42:3342-55(1999)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>A14</td> <td>Qu, et al. "A role for melanin-concentrating hormone in the central regulation of feeding behaviour: Nature 380:243-247(21 March 1996)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>A15</td> <td>Beilstein Registry Number 5345411, XP-002155831, (5/4/1993)</td> <td></td> <td></td> <td></td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>						EXAMINER	REF	REFERENCE	DATE	CLASS	REMARKS	MF	A12	Mewshaw, et al. "New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D <sub>2</sub> Agonist Pharmacophore. Structure-Activity Relationships of a Series of 2-(Aminomethyl)chromans" JOURNAL OF MEDICINAL CHEMISTRY 40:4235-56 (1997)				A13	Birch, et al. "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D <sub>2</sub> Antagonists/5-HT <sub>1A</sub> Partial Agonists with Potential as Atypical Antipsychotic Agents" JOURNAL OF MEDICINAL CHEMISTRY 42:3342-55(1999)				A14	Qu, et al. "A role for melanin-concentrating hormone in the central regulation of feeding behaviour: Nature 380:243-247(21 March 1996)				A15	Beilstein Registry Number 5345411, XP-002155831, (5/4/1993)																																																																										
EXAMINER	REF	REFERENCE	DATE	CLASS	REMARKS																																																																																																		
MF	A12	Mewshaw, et al. "New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D <sub>2</sub> Agonist Pharmacophore. Structure-Activity Relationships of a Series of 2-(Aminomethyl)chromans" JOURNAL OF MEDICINAL CHEMISTRY 40:4235-56 (1997)																																																																																																					
	A13	Birch, et al. "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D <sub>2</sub> Antagonists/5-HT <sub>1A</sub> Partial Agonists with Potential as Atypical Antipsychotic Agents" JOURNAL OF MEDICINAL CHEMISTRY 42:3342-55(1999)																																																																																																					
	A14	Qu, et al. "A role for melanin-concentrating hormone in the central regulation of feeding behaviour: Nature 380:243-247(21 March 1996)																																																																																																					
	A15	Beilstein Registry Number 5345411, XP-002155831, (5/4/1993)																																																																																																					
EXAMINER: <i>MF</i>	DATE CONSIDERED: 4/27/2005																																																																																																						